Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total		Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021			36,083,301
Beginning balance at Dec. 31, 2021	$ 199,059		$ 3	$ 414,348	$ (201)	$ (215,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)			15,606
Vesting of restricted stock awards	1			1
Option exercises (in shares)			63,552
Option exercises	51			51
Stock-based compensation expense	3,531			3,531
Net unrealized gain (loss) on short-term investments and cash equivalents	(749)				(749)
Net loss	(28,100)					(28,100)
Ending balance (in shares) at Mar. 31, 2022			36,162,459
Ending balance at Mar. 31, 2022	$ 173,793		$ 3	417,931	(950)	(243,191)
Beginning balance (in shares) at Dec. 31, 2022	48,941,254		48,941,254
Beginning balance at Dec. 31, 2022	$ 313,342	[1]	$ 5	653,707	(1,958)	(338,412)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued in a public offering, net of offering expenses (in shares)			9,583,334
Common stock issued in a public offering, net of offering expenses	269,915		$ 1	269,914
Option exercises (in shares)			454,314
Option exercises	3,661			3,661
Stock-based compensation expense	11,923			11,923
Net unrealized gain (loss) on short-term investments and cash equivalents	627				627
Net loss	$ (37,548)					(37,548)
Ending balance (in shares) at Mar. 31, 2023	58,978,902		58,978,902
Ending balance at Mar. 31, 2023	$ 561,920		$ 6	$ 939,205	$ (1,331)	$ (375,960)

[1] The condensed balance sheet as of December 31, 2022 has been derived from the audited financial statements as of that date.